Dynamiclear Safety Information

Download the full Consumer Medicine Information leaflet
for detailed safety advice regarding DYNAMICLEAR.

DYNAMICLEAR is an Approved Medicine

DYNAMICLEAR is a TGA Listed Medicine.

A Search for the Registration of DYNAMICLEAR can be done through the Therapeutics Goods Administration (TGA) Government website.

The TGA is respected as being one of the strictest and most difficult regulatory organizations to gain approval for in the world. Being a TGA Listed Medicine means that DYNAMICLEAR has been thoroughly reviewed by Government Health Authorities and has been assessed for safety, quality control and efficacy.

The Food and Drug Administration (FDA) in the United States and the Medicines and Healthcare products Regulatory Agency (MRHA) in the UK and other health authorities around the world recognize TGA Registration.

You can read the basic requirements for obtaining approval on the TGA Government website: http://www.tga.gov.au/industry/basics.htm

DYNAMICLEAR is manufactured in a Pharmaceutical GMP Certified Laboratory

Not only is DYNAMICLEAR registered as a TGA listed medicine but it is also manufactured in a Pharmaceutical Good Manufacturing Practice (GMP) compliant laboratory that is independently inspected for Sanitary, Quality Control and Safety.

GMP Certification is a strict health code that is recognized by health industries in the United States, Canada, Australia, Japan, the UK, Europe and other countries. The application of GMP standards guarantees the quality, hygiene and consistency of all of the batches that DYNAMICLEAR produce.

The Ingredients in DYNAMICLEAR are Certified to be Gentle and Non-toxic to healthy skin

The Therapeutic Goods Administration (TGA) of Australia and the European Medicine Ethics Agency approve 5% Cupric sulfate (the active ingredient in DYNAMICLEAR) to be "SAFE when used topically on skin infections on Humans". The DYNAMICLEAR product contains no more than 5.0% of Cupric sulfate.

DYNAMICLEAR also contains high quality herb extractions of Hypericum perforatum and Calendula officinalis, both of these herbs are generally well tolerated and are unlikely to cause any reaction in most people unless an allergy is present.

Effectiveness and Safety of Dynamiclear is published in the Journal of Drugs and Dermatology

The New York based Journal of Drugs in Dermatology, one of the most credible sources for new medical developments in the field of skin care, published early in 2012 that:

"The DYNAMICLEAR formulation was well tolerated, and efficacy was demonstrated in a number of measured parameters, which are helpful in the symptomatic management of HSV-1 and HSV-2 lesions in adult patients. Remarkably, the effects seen from this product came from a single application."

Read the Journal's FULL REVIEW of the Dynamiclear Clinical Trial (PDF file)

The Journal of Drugs in Dermatology assessed and reviewed the clinical trial of Dynamiclear over a period of several months before publishing their findings in the February 2012 Volume 11, Issue 2 edition of the JDD.

The Dynamiclear clinical trial was carried out in compliance with the internationally recognized ICH GCP: "Guidelines for Clinical Trials on Pharmaceutical Products in India GCP Guidelines" which was issued by Central Drugs Standard Control Organization, Ministry of Health, Government of India.

The DYNAMICLEAR Clinical Study design and conduct complied with the ethical principals originated from the Declaration of Helsinki. All changes to the protocol were approved by the IEC. IEC approval number and date were: SC/111/06 version 07 31 May 06.